Infection of human B lymphocytes with Epstein-Barr virus (EBV) in vitro
Introduction
p53 is a multifunctional protein involved in the control of cell growth and cell death (for reviews see . Wild-type p53 (wtp53) is expressed in normal cells at low levels. It accumulates in response to DNA damage and promotes growth arrest and\or apoptosis, largely depending on the cell type (Baker et al., 1990 ; Yonish-Rouach et al., 1991) . p53-mediated apoptosis and growth arrest are triggered by different mechanisms. p21\waf-1, a downstream target of wtp53 and a dual inhibitor of cyclin-dependent kinases and proliferating cell nuclear antigen, is partly responsible for p53-mediated growth arrest (Brugarolas et al., 1995 ; Chen et al., 1996 b ; Deng et al., 1995) . Recent studies indicated that p21 can actually protect cells Author for correspondence : Katja Pokrovskaja.
Fax j46 8 33 04 98. e-mail katpok!mtc.ki.se from p53-mediated apoptosis. A colorectal cancer cell line underwent growth arrest in response to wtp53 overexpression. Inactivation of p21 by homologous recombination in this cell line led to apoptosis in response to wtp53 overexpression (Polyak et al., 1996) . The mechanism by which p53 contributes to apoptosis is less well understood. It is noteworthy that p53 mutants with a defective transactivating ability can still induce apoptosis (Caelles et al., 1994 ; Chen et al., 1996 b) . Lassus et al. (1996) suggested that wtp53 can either promote apoptosis or protect from death, depending on the level present. They found that low to moderate levels of wtp53 protected immortalized mouse fibroblasts from serum-withdrawalinduced apoptosis.
Endogenous wtp53 is under the control of its cellular inhibitor, MDM2. MDM2 binds the transcriptional activation domain of p53 and blocks its transactivating ability (Picksley & Lane, 1993) . It can interfere with both p53-mediated growth arrest and apoptosis . It promotes the proteosome-mediated degradation of p53 (Haupt et al., 1997 ; Kubbutat et al., 1997) . On the other hand, p53 activates MDM2 gene expression in an autoregulatory feedback loop. The interval between p53 activation and subsequent MDM2 accumulation defines a time window during which p53 exerts its effects (Perry et al., 1993) . MDM2 may control basal p53 levels. In the absence of MDM2, p53 accumulates uncontrollably : the lethal phenotype of MDM2 knock-out mice is rescued by p53 inactivation (Jones et al., 1995 ; Montes de Oca Luna et al., 1995) .
EBV is the most efficient immortalizing virus. It is noteworthy that unlike most cultured cell lines, neither recent nor long established lymphoblastoid cell lines (LCLs) or their in vivo counterpart, the EBV-induced lymphoproliferations in immunodeficient patients, carry p53 mutations as a rule (Farrell et al., 1991 ; Edwards & Raab-Traub, 1994) . Moreover, LCLs established from Li-Fraumeni patients with a germline p53 mutation maintained the wild-type allele during in vitro culturing (Lalle et al., 1995) . EBV may have evolved a strategy to impair p53 function, in analogy with the small DNA tumour viruses that encode proteins capable of binding and inactivating p53. EBV encodes LMP-1, a protein that can protect from p53-induced cell death through the induction of the bcl-2 (Okan et al., 1995) or A20 gene (Fries et al., 1996) . On the other hand, LCLs remain sensitive to the p53-dependent apoptosis-inducing effect of the genotoxic agent cisplatin (Allday et al., 1995 a, b) and to gamma-irradiation (Williams et al., 1996) . This indicates that the apoptosis-triggering function of p53, elicited by DNA damage, is not compromised by EBVinduced immortalization.
p53 is induced following EBV infection of B cells at the transcriptional level (Allday et al., 1995 b) . EBV-infected cells are p53-positive by immunostaining during the first 3 days after virus exposure (Szekely et al., 1995) . The present study focused on the question of whether the EBV-induced p53 expression in the course of immunoblast transformation was associated with apoptosis or was, on the contrary, compatible with normal cell cycle progression. We found that the latter was the case. We have also shown that the phenomenon is not EBV-specific but immunoblast-specific, since it could be induced by a non-viral mitogen as well.
Methods
Cell lines and culture conditions. All cell lines were grown in Iscove's cell culture medium supplemented with 10 % heat-inactivated FBS, 2 mM -glutamine, 100 U\ml penicillin and 100 U\ml streptomycin. The cells were passaged 1 : 10 every fourth day. Cultures were regularly tested for the absence of mycoplasma. IARC171 and IB-4 are the old, established LCLs, carrying the B95-8 EBV strain. LCL970402 was established in the course of this study by the infection of peripheral B lymphocytes with the B95-8 EBV strain and was 3 months old at the time of analysis.
For the induction of p53-dependent apoptosis, the LCL IARC171 was treated with 5 µg\ml of a genotoxic drug, mitomycin C (Sigma), for 30 h.
B cell purification, EBV infection and mitogen stimulation.
Human peripheral blood lymphocytes were purified from the buffy coat fraction of blood from healthy donors by centrifugation on a Lymphoprep gradient (Nycomed). B cells were isolated by incubation with Dynabeads coated with anti-CD19 antibody for 1 h at 4 mC following the manufacturer's instructions (Dynal). B cells were cultured in Iscove's modified Dulbecco's medium as described above for the cell lines.
Separated B cells were infected with B95-8 supernatant for 1 h at 37 mC and, after washing, cultured further as described above. The efficiency of EBV infection in our experiments varied between 20 and 25 %, as indicated by the frequency of EBNA-5 (EBNA-LP)-or EBNA-2-positive cells after 48 h. For mitogen activation, CD19 + B cells were cultured in the presence of gamma-irradiated (10 000 rad) CD40L-expressing L cells (Garrone et al., 1995) (obtained from Pierre Garrone, Shering-Plough, France) and 1500 U\ml of recombinant IL-4 (Genzyme). The cells were removed from the beads prior to the preparation of slides or cell lysates.
Western blot and immunostaining. Total cell extracts were prepared by direct lysis in Laemmli buffer without bromophenol blue. The protein concentration was measured by the Bradford method using a Bio-Rad protein assay kit. Samples containing 30 µg of protein were separated by 10 % or 12 % SDS-PAGE followed by transfer to nitrocellulose membrane (Schleicher & Schuell) . Blocking and incubation with antibodies were performed in 5 % milk in PBS and 0n2 % Tween 20. Immunodetection using the ECL system (Amersham) was performed according to the manufacturer's instructions.
For immunofluorescence, the cells were cytospun on glass slides and fixed in cold methanol\acetone for 10 min followed by rehydration in PBS for 30 min to 1 h. When the fixation in 3 % paraformaldehyde for 20 min was used, it was followed by 3 min permeabilization in 0n1% Triton X-100. Immunostainings were performed as described (Szekely et al., 1995) . The slides were mounted with balanced salt solution : glycerol (1 : 1) containing 2n5 % 1,4-diazabicyclo[2.2.2]octane (Sigma). Bisbenzimide (Hoechst 33258) was added at a concentration of 0n4 µg\ml to the secondary antibody for DNA staining.
Fluorescence intensities were measured in the nuclei of individual immunostained cells by a combined use of a cooled charged coupled device (CCD) camera and image quantification software. Different fluorochromes were used to detect different proteins and\or DNA. Multiparameter analysis permitted a fairly precise comparison of individual cells on the same slide. The images were recorded on a DAS microscope Leitz DM RB with a Hamamatsu dual mode cooled CCD camera C4880. For quantification of the DNA content, the program ImagePro-Plus was used. The calculations were made in Microsoft Excel.
The double staining for p53 or p21 proteins and BrdU was performed as previously described (Lukas et al., 1995 ; Pagano et al., 1994) . For double p53 and TUNEL, and EBNA-2 and TUNEL stainings, the slides were fixed in paraformaldehyde. First, the p53 or EBNA-2 immunostaining was performed, followed by a TUNEL protocol (Gavrieli et al., 1992) .
The following antibodies were used : a MAb against human p53 protein, DO7 (DAKO) ; a MAb against human p21, clone 70 (Transduction Lab) ; an anti-EBNA-5 MAb, JF186 (Finke et al., 1987) ; an anti-EBNA-2 MAb, clone pe2 ; MAb IF2 against MDM2 protein (Oncogene Science) ; and an FITC-conjugated anti-BrdU MAb (Becton Dickinson). FITC-conjugated rabbit anti-mouse serum and biotinylated rabbit antimouse Fab # were from DAKO and Texas red streptavidin was from Vector Lab.
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Results
Activated B blasts are p53-positive in the absence of apoptosis CD19 + B cells isolated from the blood of healthy individuals were infected with the B95-8 strain of EBV. About 20-25 % of the cells became EBNA-positive between 24 and 48 h after infection, as judged by EBNA-5 (EBNA-LP) or EBNA-2 staining, concomitantly they transformed into blasts and started to proliferate. Immunostaining 48 and 72 h postinfection with anti-p53 MAb DO7 and, in parallel, with anti-EBNA-2 MAb pe2, showed that the percentage of p53-and EBNA-2-positive blasts was approximately the same (not shown and Fig. 1 A-C) . All the EBNA-positive cells become p53-positive 2 and 3 days after infection, as we showed in our previous study by double staining (Szekely et al., 1995) . No p53 staining was detected in resting B lymphocytes.
EBV-infected B cell cultures are littered with apoptotic cells during the first week after infection. In order to examine whether p53 expression is associated with apoptosis, the cells were double-stained for p53 and DNA ends according to the TUNEL protocol 48 h after infection (Fig. 1) . None of the p53-positive cells gave a positive TUNEL reaction, however, and none of the TUNEL-positive cells were p53-positive in the EBV-infected cultures ( Fig. 1 A, B) . Double staining for EBNA-2 and TUNEL showed that none of the EBNA-2-positive cells was TUNEL-positive ( Fig. 1 C) . This indicated that all EBVinfected B cells that expressed EBNA-2 were protected from apoptosis at this time-point.
In order to study whether p53-positive staining can be detected in the apoptotic cells, we have induced apoptosis in the LCL IARC171 by a DNA-damaging agent, mitomycin C. LCLs in general bear no p53 mutations. Genotoxic drugs and gamma-irradiation induce accumulation of wtp53 and wtp53-dependent apoptosis in the LCLs (Allday et al., 1995 a, b) . IARC171 cells were treated with 5 µg\ml of mitomycin C for 30 h. p53 protein has accumulated in the cells as judged by staining with anti-p53 MAbs. Many apoptotic cells were detected in the mitomycin-C-treated cultures by Hoechst staining. The double staining for p53 and TUNEL revealed that p53 can be readily detected in the apoptotic cells (Fig. 1 D-F) . This finding suggested that the absence of p53 in the apoptotic cells of the EBV-infected cultures was not due to protein degradation.
CD40 ligation protects peripheral blood and germinal centre B cells from apoptosis, and in the presence of IL-4 induces B cell activation and proliferation (Banchereau et al., 1991 ; Liu et al., 1989) . In a parallel experiment, B cells were activated for 3 days by CD40L and IL-4. About 7 % of the activated cells were p53-positive. The CD40L plus IL-4-exposed B cell cultures were essentially free of apoptotic cells after 3 days, as judged by Hoechst staining of the nuclei and JIJ K. Pokrovskaja and others K. Pokrovskaja and others TUNEL staining. The p53-positive cells also appeared viable and healthy (not shown).
p53-positive cells can enter the S phase
The cell cycle distribution of p53-positive and -negative cells was assessed by image analysis (Fig. 2) . The images of the DNA (Hoechst 33258) and p53 stainings of the individual fields of the slide were captured, and the staining intensity of individual nuclei was measured. Each cell in the field was given a number. The measurements of DNA staining intensities allowed us to obtain the cell cycle distribution among the cells in each field. Fig. 2 (A) shows an enlarged part of the image of Hoechst and p53 staining of the cells, combined with the cell cycle data of the entire field of 80 cells, depicted as bars at the top. Analysis revealed that many cells with 2N DNA content were p53-positive ; cell N.66 is shown as an example. Some cells that entered prophase and metaphase, as assessed by the morphology of nuclei stained by Hoechst, expressed high levels of p53 (Fig. 2 B, C, respectively) .
To confirm by an independent method that p53-expressing cells could enter the S phase, EBV-infected B cells were pulselabelled with BrdU 72 h after virus exposure and doublestained for p53 and BrdU. The results are summarized in Table  1 . Fig. 3 (D-F) shows two large blasts surrounded by noninfected and apoptotic cells. Both are positive for p53 and BrdU. Although the proportion of BrdU-positive cells in the EBV-infected cultures varied from experiment to experiment, about 50 % of the large blasts incorporated BrdU 70 h post-EBV infection. Among p53-positive cells, 65 % were positive for BrdU (Table 1) .
Fifteen per cent of the CD40L plus IL-4-activated B cells were in S phase after 3 days. EBV, thus, induces DNA synthesis in the infected B cells much more efficiently compared to the CD40 and IL-4 treatment. Among the p53-positives, 87 % entered S phase during an incorporation period of 1 h as detected by BrdU (Table 1 ; Fig. 3 G-I) .
The same experiment was also carried out on exponentially growing IARC171 LCL cells (Table 1 ; Fig. 3 A-C). About 26 % of them were in the S phase as judged by pulse BrdU labelling. About 5 % of the cells expressed p53 with varying staining intensity. Some of these cells were more brilliantly stained than the freshly infected p53-positive cells. However, only a minority of the p53-positive cells (28 %) incorporated BrdU, in contrast to the majority in the EBV-infected and the mitogenactivated B cells.
Expression of p21/waf-1 and MDM2 in EBV-infected and mitogen-stimulated B cells
Our finding that p53 expression did not interfere with cell cycle progression and was not associated with apoptosis in activated B cells raised the question of whether the protein was functional. This was approached by testing the expression of the downstream genes p21\waf-1 and MDM2, in parallel with p53 itself in the EBV-infected and CD40L and IL-4-stimulated B cells by Western blotting. Established LCLs were tested in parallel (Fig. 4) .
Equal amounts of total cell lysates were used for immunoblotting. In spite of the fact that the efficiency of EBV infection was only 20 % (see Methods) and that 50 % of the uninfected cells remained viable even after 72 h, there was an increase in p53 levels at 24, 48, 72 h and 6 days after EBV infection, in comparison with 24 h old cultures of uninfected cells. It should be pointed out that there is always a spontaneous (EBVindependent) B cell activation in the unstimulated cultures, compared to freshly purified cells, with concomitant appearance of cells with nuclear p53 staining (not shown). This activation may account for the presence of a weak p53 band in the lysate from uninfected B cells. MDM2 expression showed a gradual increase 1-6 days post-infection, whereas the p21 protein became readily detectable only at day 6 post-infection (Fig. 4) .
Immunoblotting showed a similar increase of p53 and MDM2 in CD40L and IL-4-activated B cells after 70 h, compared to the 6-day-old EBV-infected cultures. p21 protein K. Pokrovskaja and others K. Pokrovskaja and others actually attained a higher level, compared to the EBV-infected cells at corresponding time-points (Fig. 4) .
Three independently established LCLs (LCL970402, IARC171, IB4) were used for comparison. Total lysates showed similar levels of p53 and MDM2 to the 6-day-old EBVinfected or mitogen-activated cultures. In contrast, the p21 levels were significantly higher in all three LCLs than in either EBV-infected or mitogen-activated B cells.
In line with the immunoblotting data, p21 was hardly detectable by immunostaining in the EBV-infected or in the mitogen-stimulated B cells (few positive cells per slide). In contrast, the LCLs contained strongly stained cells, amounting to 0n5-1 % of the population. Interestingly, pulse-labelling of three different LCLs with BrdU and double staining for p21 and BrdU showed that all p21-positive cells were BrdUnegative (not shown).
MDM2-specific immunostaining was detected 24 h after EBV infection or CD40L plus IL-4 stimulation (Fig. 5) . Starting from this time-point, all the activated large blasts with decondensed chromatin and large cytoplasm were MDM2-positive in both cultures, whereas small resting B cells remained negative. Unlike p21, which was restricted to a minority of the cells, 98 % of the IARC171 and IB-4 cells were MDM2-positive.
JJC p53 in EBV-infected B cells p53 in EBV-infected B cells Fig. 4 . Western blotting for p53, p21/waf-1 and MDM2 expression as a function of time after EBV infection or mitogen activation of B cells. Equal amounts of protein were separated in parallel by 10 % PAGE to detect MDM2 and by 12 % PAGE for the p21 and p53 detection. The same filter was probed with anti-p21 MAb followed by ECL detection, washed in PBS and then probed with anti-p53 MAb. 
Discussion
We have found that activation of wtp53 expression in normal, ex vivo B cells by EBV infection or mitogenic stimulation is not associated with growth arrest or apoptosis. EBV is a powerful B cell activator. A total of 50 % or more EBNA-positive cells were in S phase 3 days after infection as shown by BrdU incorporation. Nearly all the EBNA-positive cells were also p53-positive by immunostaining. None of them was TUNEL-positive, indicating that p53 did not induce apoptosis in these cells. Moreover, the majority of the p53-positive cells entered S phase. Even some of the mitotic cells showed strong p53 staining. The compatibility of wtp53 expression with DNA replication and mitosis has not been demonstrated before at the single cell level. Therefore, we asked whether this phenomenon is confined to the EBVinfected cells. We found that CD40 ligation in the presence of IL-4 during the first 3 days induced p53 expression in 7 % of the cells. It is noteworthy that most p53 expressors were in the S phase, as detected by BrdU incorporation followed by double staining. Neither the nontransforming P3HR1 strain of EBV, which lacks the EBNA-2 gene, nor UV-inactivated EBV can induce S phase in B cells (Kieff, 1996) . Earlier studies have shown that none of these agents can induce p53 expression in B cells (Allday et al., 1995 b ; Chen & Cooper, 1996) . Taken together, the data suggest that p53 induction by EBV or mitogens is related to cellular activation and proliferation.
There are other examples of p53 induction in activated cells. p53 expression increased in PHA-stimulated T lymphocytes and reached peak levels in late G " \early S phase. The induction of p53 was dependent on the presence of the T cell mitogen, IL-2 (Mercer & Baserga, 1985) . An increase in p53 levels was also found in serum-stimulated human fibroblasts (Reich & Levine, 1984) . Moreover, expression of a p53 antisense construct in NIH3T3 cells that carried wtp53 led to complete cessation of DNA synthesis (Shohat et al., 1987) , suggesting that an unknown p53 function might be required for progression through the cell cycle.
The growth suppressor activity of p53 largely depends on its transactivation capacity (Crook et al., 1994 ; Pietenpol et al., 1994) . In order to find out whether p53 is transcriptionally active in the EBV-infected and mitogen-stimulated B cells, we examined the expression of two p53 downstream genes, MDM2 and p21. Immunoblotting showed that the MDM2 levels rose rapidly after both EBV infection and mitogen stimulation. Strong MDM2-specific immunostaining was detected in parallel with p53 expression after 24 h. This would suggest that p53 had maintained its transactivation function. A similar conclusion was reached by Chen & Cooper (1996) , who studied p53, MDM2 and p21 induction after EBV infection of B cells. However, MDM2 can inhibit p53 function and even decrease the p53 levels by inducing p53 degradation (Haupt et al., 1997 ; Kubbutat et al., 1997) . The rapid induction of MDM2 in our experiments suggested that it might interfere with p53-mediated transactivation of other target genes and\or with p53-induced apoptosis. Accordingly, we did not detect any p21 immunostaining during the first 3 days after EBV infection or mitogen exposure. Immunoblot data confirmed this finding. Somewhat higher p21 levels, compared to the EBV-infected cultures, were found in the CD40L and IL-4-activated cells by immunoblot. This suggests that p53 does not transactivate p21 expression in activated B cells.
EBV-immortalized LCLs maintain their wtp53 expression, which is readily detectable by immunoblotting. Elevated wtp53 levels have been reported in some tumour cells. A total of 31 out of 70 non-Hodgkin's lymphomas had wtp53 genes, as determined by single-strand conformational polymorphism analysis, confirmed by sequencing of the entire coding region (Maestro et al., 1997) . 19 out of 31 expressed high wtp53 levels as indicated by immunostaining. 10 of them expressed p21, shown by immunostaining of serial sections. Co-accumulation of p53 and Ki-67, studied by analysis of the serial sections, suggested that wtp53-bearing cells were actively proliferating. F9 teratocarcinoma cells expressed high wtp53 levels that decreased upon differentiation (Oren et al., 1982) . The tolerance of high wtp53 levels in transformed epithelial cells was found to be dependent on the high MDM2 levels and complex formation with p53 (Blaydes et al., 1997) . The wtp53 expressed at high levels in murine teratocarcinoma lines was found to be largely inactive (Lutzker & Levine, 1996) .
Is p53 active in the LCLs? p53 can be induced in the LCLs by the DNA-damaging agent cisplatin (Allday et al., 1995 b) and by gamma-irradiation (Williams et al., 1996) , leading to apoptosis. We found that the individual cells that expressed high p53 levels in LCLs were arrested in their proliferation, since the majority failed to enter S phase during pulse-labelling with BrdU. These data suggest that p53 induction can arrest growth in established LCLs.
We have found a striking difference between the p53 expression of LCLs and freshly EBV-infected or mitogenstimulated B cells. (1) All B blasts were positive 2 days after infection but only up to 5 % positive cells could be found in LCLs. (2) p53 immunostaining was compatible with DNA replication in freshly activated B cells but not in the established LCLs. (3) There was also a difference in p21 expression : all established LCLs that were studied expressed high total p21 mRNA and readily detectable protein, as found by Northern blot (data not shown) and immunoblotting (Fig. 4) , respectively. Immunostaining showed p21 expression in only 0n5-1 % of the LCL population, however. Established LCLs are heterogeneous with respect to the proliferating capacity of the cells. LCLs have low cloning efficiency in limiting dilution experiments, reflecting the low number of cells that are able to undergo self-maintaining division. Moreover, some LCL lines can generate non-proliferating, immunoglobulin-secreting plasma cells (Wendel-Hansen et al., 1987) . We regularly detect small resting cells in LCL cultures (L. Szekely, unpublished) .
Interestingly, the p21-positive cells were consistently BrdU-negative in pulse-labelling experiments, suggesting that they were either temporarily or permanently arrested in their growth. It remains to be seen whether the p21 expression in LCLs is the result of p53-dependent transactivation or is independent of p53 and whether it contributes to growth arrest and\or differentiation.
